CRY-1, a regulator of our circadian clocks, contributes to disease spread and poor outcomes in prostate cancer patients by boosting DNA repair mechanisms that render cells more resistant to treatments, a study reveals. The findings support further investigation of CRY-1 as a therapeutic target, especially in prostate cancers that fail to respond to current therapies. The study, “The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair,” was published in the journal Nature…
You must be logged in to read/download the full post.
The post Biological Clock Protein CRY-1 Eyed as Therapeutic Target appeared first on BioNewsFeeds.